Table 3. Summary of Grade 3–5 Adverse Events across Dose Levels.
Included in this table are adverse events experienced in at least 2 patients, or adverse events that were classified as treatment-related in at least 1 patient.
| All AEs n(%) | Treatment-Related n(%) | |||
|---|---|---|---|---|
| Adverse Event Name | Grade 3 | Grade 4 | Grade 5 | Grades 3–5 |
| Alk phos | 1 (5) | 0 | 0 | 1 (5) |
| ALT elevation | 2* (10) | 0 | 0 | 2 (10) |
| Neutropenia | 6* (29) | 1 (5) | 0 | 7 (33) |
| Bilirubin elevation | 2 (10) | 0 | 0 | 0 |
| Colitis | 0 | 1 (5) | 0 | 1 (5) |
| Dyspnea | 0 | 1 (5) | 0 | 1 (5) |
| Edema | 1 (5) | 0 | 0 | 1 (5) |
| Fatigue | 2 (10) | 0 | 0 | 1 (5) |
| Hemoglobin | 2 (10) | 0 | 0 | 0 |
| Hyperglycemia | 2 (10) | 0 | 0 | 0 |
| Hypophosphatemia | 1 (5) | 0 | 0 | 1 (5) |
| Lymphopenia | 3 (14) | 0 | 0 | 3 (14) |
| Thrombocytopenia | 2 (10) | 0 | 0 | 2 (10) |
| Pneumonitis | 0 | 0 | 1* (5) | 1 (5) |
| Skin rash | 1 (5) | 0 | 0 | 1 (5) |
| Ulcer | 1 (5) | 0 | 0 | 1 (5) |
| Vomiting | 3 (14) | 0 | 0 | 0 |
*
Includes at least one DLT.